-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
Today (November 22), the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that the IBI397 declared by Cinda Biologics has obtained an implied license for a clinical trial and intends to develop the treatment of advanced malignant tumors
Screenshot source: CDE official website
In the human body, there is a type of white blood cells called macrophages, which can distinguish between "foe and self" and eliminate pathogens and abnormal cells without harming normal cells
However, studies have found that tumor cells can use the CD47-SIRPα signaling pathway to escape the attack of the natural immune system
AL008 is a new type of anti-SIRPα antibody developed by Alector
In preclinical humanized mouse tumor models, AL008 single agent has shown the properties of inhibiting tumor growth and enhancing the activity of M1 macrophages
In addition, AL008 can also promote the function of T cells
It is hoped that the follow-up clinical research of the drug will proceed smoothly and achieve good results, which will bring new treatment options to patients as soon as possible
Reference materials:
[1] Center for Drug Evaluation of China National Medical Products Administration.
